AstraZeneca's COVID-19 vaccine candidate demonstrates a significant 70% efficacy in large trials, with an optimal dosing regimen achieving 90% effectiveness. At the same time, Regeneron's antibody treatments, casirivimab and imdevimab, receive FDA approval, marking crucial milestones in the fight against the pandemic. These advancements enhance the companies' positions in healthcare and are expected to influence market investor sentiment. Earlier, Amgen faced legal challenges over its cholesterol drug Repatha, and Regeneron reported a successful Phase 3 trial for Dupixent, potentially expanding its sales in treating chronic obstructive pulmonary disease.
Click a month on the chart to update the report below.
